NEWSROOM

4VITAHEALTH Launches Groundbreaking Mental Health Supplements

4VITAHEALTH Launches Groundbreaking Mental Health Supplements

Tucson, Arizona, October 15, 2024 - PRISM MediaWire - 4VITAHEALTH, a pioneering mental health and wellness supplement company, is proud to announce the launch of its all-natural, made in the USA supplements designed to support brain health and enhance mental well-being. The Epidemic of Sleep Deprivation, Low Mood, and Brain Fog In the United States, approximately 30% of the population (around 100 million people) suffer from sleep deprivation, 23% (around 60 million people) experience some type...

read more
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions

BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions

Vendaje AC to launch across MAC regions nationwide through Venture Medical, the Company’s exclusive sales and marketing partner for AmnioWrap2® POMPANO BEACH, Fla., Oct. 15, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that the Center for Medicare Services (CMS) has established national pricing for its allograft...

read more
Sono-Tek Reports Fiscal Second Quarter and First Half 2025 Financial Results, Record Backlog and Provides Revenue Guidance

Sono-Tek Reports Fiscal Second Quarter and First Half 2025 Financial Results, Record Backlog and Provides Revenue Guidance

Q2 Sequential Revenue Growth Meets Quarterly Guidance of 2%-5% Record Equipment and Service Backlog of $11.7 Million First Half Revenue Growth of 10% YOY, First Half Net Income Growth of 13% YOY Expects Continued Revenue Growth for Full Fiscal Year 2025 Conference Call Today at 10:00 am ET MILTON, N.Y., October 15, 2024 – PRISM MediaWire -  Sono-Tek Corporation (Nasdaq: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today reported financial results for the second...

read more
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences

Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences

KLTO strengthens team with industry veteran and is poised to accelerate the development of its therapeutic candidates New York, NY, October 15, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). “We are thrilled to have Peter join Klotho...

read more
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

Patent application covers key technology innovations for delivering therapeutic agents Proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, PA, October 15, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage...

read more
SPZI: JP 3E Holdings, Inc. Accelerates Growth with Major Corporate Milestones Toward Uplisting

SPZI: JP 3E Holdings, Inc. Accelerates Growth with Major Corporate Milestones Toward Uplisting

NEW YORK, October 14, 2024 – PRISM MediaWire - JP 3E Holdings, Inc. (OTC: SPZI), formerly Spooz, Inc., is excited to announce a series of significant corporate developments that mark a new era of growth and expansion for the company. These strategic initiatives include steps to uplist to the OTCQB market, filing a Form 10, following which, it will initiate 15c2-11 filing, become a fully reporting company under SEC guidelines, remove the "shell risk" designation, and implement a comprehensive...

read more
In Light of World Mental Health Day, PRISM Highlights Mental Health Index Companies Making a Difference

In Light of World Mental Health Day, PRISM Highlights Mental Health Index Companies Making a Difference

New York, New York, October 10, 2024 - PRISM MediaWire - PRISM MediaWire - Mental health has not always been a topic to discuss as easily as other health related topics due to the stigma surrounding it. Those who have identified having a mental health condition typically do not seek the proper help or treatment for fear of judgement or admission to being unstable. The reality of it is that whether or not you have a condition, we all need to do things to ensure we have good mental health in the...

read more
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

PITTSBURGH, Oct. 09, 2024 - PRISM MediaWire - Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024. Event: Lipella Presentation - 2024 Maxim Healthcare Virtual Summit Date: Thursday, October 17th, 2024...

read more
SKYX Provides Corporate Update, including Significant Insider Buying

SKYX Provides Corporate Update, including Significant Insider Buying

MIAMI, Oct. 09, 2024 - PRISM MediaWire - SKYX (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive smart platform technology company with over 97 issued and pending patents in the U.S. and globally, and which owns over 60 lighting and home décor websites with a mission to make homes and buildings become smart, safe, and advanced as the new standard, provides today a corporate update including significant insider buying. SKYX Secures $11 million equity preferred stock investment...

read more
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., October 8, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test,...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850